Genome In-Vivo Medicine Pharma Companies 
pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Zinc fingers. billion in funding.
XTalks
DECEMBER 20, 2023
In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. Below are some of the key trends that will be shaping the future of the life sciences in 2024 and beyond.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Camargo
NOVEMBER 11, 2020
In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks. Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. In October, the U.S.
The Pharma Data
OCTOBER 14, 2020
VBL has recently demonstrated ex-vivo activity of anti-MOSPD2 antibodies in patients with relapsing-remitting and progressive multiple sclerosis (MS), as well as in animal models of rheumatoid arthritis (RA), nonalcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD). 1. -- -->. -- [if lte IE 8]--> .
Drug Discovery World
NOVEMBER 15, 2022
Developed with the idea of engineering an enzyme called terminal deoxynucleotidyl transferase (TdT), a type of DNA polymerase, these enzymatic DNA synthesis methods are now the focus of dozens of companies. Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. .
Expert insights. Personalized for you.
142 
Let's personalize your content